MIBG scintigraphy and Strain Echocardiography in the early detection of late cardiovascular effects of (neo)adjuvant breast cancer treatment with docetaxel, doxorubicin and cyclophosphamide (TAC): a pilot study - TOXTAC

Integraal Kankercentrum Oost0 个研究点目标入组 150 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•-Female patients with breast cancer, >= 18 years old at the time of breast cancer diagnosis
•-(Neo)adjuvant treatment with docetaxel, doxorubicin and cyclophosphamide (TAC) completed minimally one year before inclusion and maximally nine years before.

•-Evidence of breast cancer recurrence or metastatic disease
•-Evidence of heart disease at the time of breast cancer diagnosis
•-Evidence of renal failure at the time of cardiac evaluation
•-Pregnant or lactating
•-Participation in a research protocol with ionizing radiation within one year before inclusion.
•-Evidence of Diabetes Mellitus or Parkinson*s Disease
•-Evidence of an MIBG-accumulating tumor

发起方

Integraal Kankercentrum Oost